Evonik Industries AG
DUS:EVK

Watchlist Manager
Evonik Industries AG Logo
Evonik Industries AG
DUS:EVK
Watchlist
Price: 17.33 EUR 0.12% Market Closed
Market Cap: €8.1B

Evonik Industries AG
Investor Relations

Evonik Industries AG is a German specialty chemicals company. It makes ingredients and materials that other companies use to improve their own products, such as additives for coatings and plastics, feed amino acids for animal nutrition, and specialty materials for things like adhesives, cosmetics, and medical products. Its customers are mainly industrial manufacturers, agriculture and animal feed producers, and consumer-goods companies that need consistent, high-performance chemical inputs. The company sells these products through long-term supply relationships and technical service, rather than one-off consumer sales. It makes money by producing and selling specialty chemicals that are often tied to specific customer formulations or production processes, which can create recurring demand and switching costs. In many cases, Evonik is a supplier that sits in the middle of the value chain, helping its customers improve performance, efficiency, or product quality. What makes Evonik different is its focus on specialized chemistry instead of basic bulk chemicals. That means it often competes on product know-how, reliability, and close customer support, not just on price. This gives the business a role as a behind-the-scenes partner to industrial and consumer brands that need tailored chemical ingredients.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2026
Call Date
Aug 4, 2026
AI Summary
Q2 2026

Strong quarter: Evonik said Q2 was the best quarterly result in 4 years, with adjusted EBITDA up 24% year over year to EUR 630 million and above expectations.

Outlook raised: Management reiterated the upgraded full-year outlook that lifted the midpoint by EUR 250 million and said Q3 should be at least as strong as Q2, with some normalization expected in Q4.

Methionine strength: Methionine remained a major earnings driver, with management saying Q3 should be the best methionine quarter of the year and that the business should outperform most expectations in 2026.

Cost cuts expanded: Evonik extended its Tailor-made restructuring program and now plans to reduce about 3,200 more positions between 2027 and 2029, on top of earlier reductions.

Cash improved: Cash generation improved significantly, helping support the full-year target of around 40% cash conversion and reducing pressure on net financial debt seasonally.

Capital use: Management said the new dividend policy starts in May 2027 and that a share buyback is not currently on the agenda.

Key Financials
Adjusted EBITDA
EUR 630 million
Adjusted EBITDA in H1
EUR 1.1 billion
Employee reductions under Tailor-made and related programs
around 2,800
Additional employee reductions planned
3,200
Dividend per share
EUR 1
Book value of Oxeno
about EUR 50 million
Site closure restructuring charge
within EUR 50 million
Earnings Call Recording
Other Earnings Calls

Management

Dr. Harald Schwager
Deputy Chairman of the Executive Board
No Bio Available
Maike Schuh
CFO & Member of Executive Board
No Bio Available
Dr. Wilfried Ostendorf
Head of Production and Technology
No Bio Available
Mr. Tim Lange
Head of Investor Relations
No Bio Available
Mr. Thomas Mahlstedt
Vice President M&A, Corporate Legal & Compliance
No Bio Available
Christian Schmid
Head of Corporate Communications
No Bio Available
Dr. Stefan Mack
Head of the Methionine & Derivatives Product Line
No Bio Available
Mr. Matthias Ruch
Head of External Communications & Corporate Press Officer
No Bio Available
Dr. Gaetano Blanda
Head of Business Line Coating Additives
No Bio Available
Ms. Lauren Kjeldsen
Head of the Smart Materials Division
No Bio Available

Contacts

Address
NORDRHEIN-WESTFALEN
Essen
Rellinghauser Strasse 1-11
Contacts